JenaValve Technology, Inc.
Medical Equipment ManufacturingCalifornia, United States201-500 Employees
JenaValve Technology, Inc. is a medical equipment manufacturer headquartered in Irvine, California, with additional offices in Leeds, United Kingdom and Munich, Germany, and a workforce of about 201 to 500 employees. The company develops transcatheter heart valve technology, with the Trilogy Transcatheter Heart Valve System designed for minimally invasive treatment of aortic regurgitation. In the European Union, the Trilogy System is approved for the treatment of severe, symptomatic aortic regurgitation in high-risk surgical patients and is CE-mark approved for treatment of severe, symptomatic aortic stenosis. In the United States, enrollment for the ALIGN-AR IDE clinical trial has been completed to support a future PMA submission, which, if approved, would make the Trilogy System the first TAVR device indicated for symptomatic, severe AR in the US. In 2026, JenaValve announced several senior leadership appointments, including Edward Sarnowski as Chief Technology Officer, Matt Bacso as Chief Financial Officer, Maria Jose Arana as Vice President of Quality and Compliance, Tonya Porter as Vice President of Regulatory Affairs, and Dave Haan as Vice President of Clinical Affairs.
1-888-653-2347 
support@leadiq.com 
